Broadly Neutralizing Antibodies in HIV-1 Treatment
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 30 September 2025
Special Issue Editor
Interests: Retrovirus, E3 ligases, MHC
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Broadly neutralizing antibodies (bNAbs) have emerged as a promising tool in combating infectious diseases such as HIV, influenza, and SARS-CoV-2. Recent advancements have focused on identifying and engineering bNAbs that target conserved viral epitopes, enhancing potency and breadth. In vaccine design, bNAbs guide immunogen development to elicit similar immune responses, exemplified by antibodies that target conserved regions of the HIV env gene. Therapeutically, bNAbs show efficacy in preventing infection and mitigating disease severity, with improved half-life and delivery mechanisms boosting their clinical potential. However, challenges remain in the development of bNAb-eliciting vaccines and the therapeutic efficacy of bNAbs, including viral escape mutations and the eliciting of sustained responses. This Special Issue therefore delves into the development and applications of bNAbs for the treatment and prevention of HIV-1.
Dr. Zhi Yang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bNAbs, HIV-1, vaccine design, bNAb elicitation , HIV-1 treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
